Noribogainalog

 ( 5-hydroxytryptamines ) 

Noribogainalog ( nor-IBG), also known as 9-hydroxyibogaminalog, is a drug of the ibogalog family related to noribogaine. It is a simplified analogue of noribogaine.

---

Pharmacology The drug acts as a potent serotonin 5-HT_2A receptor partial agonist ( ≈ 90nM; = 35%). It also has activity as a dopamine transporter (DAT) chaperone. Noribogainalog does not affect locomotor activity, does not produce the head-twitch response, and does not affect various other physiological and behavioral measures. However, it does produce analgesic effects that can be diminished by the serotonin 5-HT_2A receptor antagonist ketanserin. The drug shows relatively low expected blood–brain barrier permeability.

---

History

Noribogainalog was first described in the scientific literature by David E. Olson and colleagues by 2021.

---

See also

• Ibogalog
• Noribogaine
• Catharanthalog
• Ibogainalog
• Ibogaminalog
• PNU-22394
• Tabernanthalog

---

External links

• Noribogainalog - Isomer Design

Categories: 5-hydroxytryptamines, Analgesics, Ibogalogs, N,n-dialkyltryptamines, Non-hallucinogenic 5-ht2a Receptor Agonists, Peripherally Selective Drugs

Post Comment